#United States #New York #Securities Fraud #Pomerantz LLP #Tyra Biosciences

Pomerantz Law Firm Investigates Tyra Biosciences Investors' Claims

Pomerantz LLP, a leading firm known for its expertise in corporate securities litigation, has commenced an investigation focused on potential claims made by investors in Tyra Biosciences, Inc. (NASDAQ: TYRA). This investigation seeks to ascertain whether Tyra and its executives have engaged in any fraudulent or illegal business practices that may have adversely affected shareholders.

The Context of the Investigation

The scrutiny arises from Tyra's recent announcement regarding the initial outcomes of its Phase 2 clinical trial, dubbed SURF302. This trial evaluated the safety and efficacy of its oral drug, dabogratinib, in patients diagnosed with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer. On September 9, 2026, Tyra reported favorable safety data; however, they also conveyed alarming figures regarding adverse events. Specifically, 14% of participants in the 60mg once-daily cohort and 9% in the 50mg cohort experienced Grade 3 treatment-emergent adverse events. This revelation may have significant implications for investor trust and company performance.

The reaction to the September press release was swift and severe. Tyra's stock saw a dramatic drop of $4.72, translating to a 17.66% decrease, closing at $22.01 per share. Such a steep decline raises questions about the integrity of the information conveyed to shareholders prior to this announcement.

Implications for Investors

Investors who feel they may have suffered losses due to Tyra's actions are encouraged to reach out to Pomerantz LLP for more information about their legal rights and potential recourse. The firm has a rich history of advocating for victims of securities fraud and protecting shareholder rights.

Danielle Peyton, a representative from Pomerantz, is handling inquiries related to this investigation. Interested parties can reach her at [email protected] or by calling 646-581-9980, extension 7980. This is an opportunity for investors to explore potential claims and join the ongoing efforts to address any alleged wrongdoing.

Pomerantz LLP's Track Record

Established over 85 years ago, Pomerantz LLP is lauded as one of the premier legal firms in the fields of corporate litigation, particularly in securities and antitrust class actions. The legacy of its founder, Abraham L. Pomerantz, emphasizes a commitment to serving class action victims and meticulously pursuing justice against corporate malfeasance. The firm has successfully secured multi-million dollar recoveries for its clients in numerous cases.

As the investigation unfolds, stakeholders in Tyra Biosciences may find solace in the fact that there are avenues available to address their concerns and potential losses.

Conclusion

The situation surrounding Tyra Biosciences presents a complex web of corporate actions and investor rights. As reports of adverse events from clinical trials unfold, all eyes will be on how the firm addresses shareholder inquiries and concerns moving forward. Investors are advised to stay informed and consider consulting legal professionals to explore their options amidst this troubling climate in the biotech sector.